| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.009 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |